Stock events for TherapeuticsMD, Inc. (TXMD)
TherapeuticsMD (TXMD) stock has increased by approximately 110.28% over the past six months. This is due to achieving net income in recent quarters, transitioning to a royalty-based model which increased license revenue and reduced operating expenses, and strong shareholder support. The stock has moved between $0.72 and $2.95 over the past year, with a share price of $2.26 as of February 27, 2026.
Demand Seasonality affecting TherapeuticsMD, Inc.’s stock price
Based on historical stock price data, January has the highest probability of positive returns for TXMD stock at 60.00%, while March has a 20.00% probability. October has the lowest probability of positive returns at 11.11%.
Overview of TherapeuticsMD, Inc.’s business
TherapeuticsMD, Inc. operates as a pharmaceutical royalty company focused on women's healthcare. The company shifted to a royalty-based model in December 2022, collecting royalties from licensees instead of engaging in R&D or commercial operations. Its major licensed products include IMVEXXY, BIJUVA, ANNOVERA, and prenatal vitamin products under the vitaMedMD and BocaGreenMD brands. The company's technology, SYMBODA, is used to develop advanced hormone therapy products.
TXMD’s Geographic footprint
TherapeuticsMD, Inc. primarily collects royalties from its licensees in the United States and its possessions and territories. The company also licenses its women's health products in the rest of the world to its exclusive licensing partners. Its headquarters are located in Boca Raton, Florida.
TXMD Corporate Image Assessment
Information directly detailing TherapeuticsMD's brand reputation is not explicitly available. However, the significant financial turnaround, achieving net income, increased license revenue, reduced operating expenses, and strong shareholder support suggest a positive perception among investors regarding the company's strategic shift to a royalty-based model. The company's news releases focus on financial results and business updates related to this royalty-based model, highlighting cost optimization and the evaluation of strategic alternatives.
Ownership
The ownership structure of TherapeuticsMD (TXMD) includes institutional investors, corporate insiders, and the general public. Institutional shareholders hold approximately 20.77% to 29.25% of the company's stock, with Vanguard owning the most shares. Insiders own about 1.55% to 1.56% of the stock, with Brian Bernick being the largest individual shareholder. Retail investors and the public hold a substantial portion, ranging from approximately 0.00% to 70.73% of the company's stock.
